Abstract:
Objective To compare the efficacy and safety of the semaglutide biosimilar JY29-2 with originator semaglutide (Ozempic) in patients with type 2 diabetes mellitus (T2DM).
Methods This was a multicenter, randomized, open-label, parallel-group, phase 3 trial. From July 1, 2022 to October 31, 2023, patients with T2DM enrolled at 34 clinical centers in China were randomized in a 1:1 ratio to receive JY29-2 or Ozempic for 32 weeks, both in combination with metformin. The primary endpoint was the change from baseline in glycosylated hemoglobin A1C (HbA1C) at week 32. An analysis of covariance (ANCOVA) model was used to perform an equivalence test on the primary efficacy endpoint, with the equivalence margin set at ±0.4%. The secondary endpoints included changes from baseline in fasting blood glucose, body weight, pulse, blood pressure and lipid profile. Treatment emergent adverse events (TEAEs), immunogenicity and pharmacokinetics (PK) were also evaluated.
Results A total of 476 patients were included, with 238 cases in each group. At week 32, the mean change from baseline in HbA1C for the JY29-2 group and Ozempic group were −1.79% (95%CI −1.94% – −1.65%) and −1.70% (95%CI −1.83% – −1.56%), respectively. No statistical difference was observed between the two groups. The least squares mean changes from baseline in HbA1C were −1.78% (95%CI −1.89% – −1.67%) in the JY29-2 group and −1.69% (95%CI −1.80% – −1.58%) in the Ozempic group. The difference in the least squares mean between the two groups was −0.08% (95%CI −0.24% – 0.07%), which fell within the pre-specified equivalence margin of −0.4% – 0.4%. No statistical differences were observed between JY29-2 group and Ozempic group for the secondary endpoints and TEAEs. The PK parameters were similar between the two groups, and anti-drug antibody (ADA) results were negative in both groups.
Conclusions The semaglutide biosimilar JY29-2 demonstrates similar efficacy and safety to Ozempic in patients with T2DM, supporting its use as an effective treatment option for T2DM.